Brief: Rigel Pharmaceuticals Inc On April 16, Received Written Notice From Eli Lilly
21/04/2026 23:25
April 21 (Reuters) - Eli Lilly and Co LLY.N: RIGEL PHARMACEUTICALS INC: ON APRIL 16, RECEIVED WRITTEN NOTICE FROM ELI LILLY RIGEL PHARMACEUTICALS INC - ELI LILLY TO TERMINATE LICENSE AND COLLABORATION AGREEMENT WITH RIGEL PHARMACEUTICALS - SEC FILING RIGEL PHARMACEUTICALS INC - AGREEMENT TERMINATION EFFECTIVE JUNE 15, 2026 - SEC FILING RIGEL PHARMACEUTICALS INC - TO REGAIN FULL RIGHTS TO LICENSED COMPOUNDS AFTER TERMINATION - SEC FILING RIGEL PHARMACEUTICALS INC - DOES NOT EXPECT FUTURE MILESTONES OR ROYALTIES UNDER AGREEMENT AFTER TERMINATION - SEC FILING Source text: [ID:n0001034842-26-000027] Further company coverage: LLY.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)